{"id":1922,"date":"2026-02-25T15:43:33","date_gmt":"2026-02-25T15:43:33","guid":{"rendered":"https:\/\/wp-productionenv-bjg9h2g2bgg5b8aa.southeastasia-01.azurewebsites.net\/news\/lambdavision-secures-starlab-leo-space-booking-with-voyager-technologies\/"},"modified":"2026-02-25T15:43:33","modified_gmt":"2026-02-25T15:43:33","slug":"lambdavision-secures-starlab-leo-space-booking-with-voyager-technologies","status":"publish","type":"post","link":"https:\/\/starpath.global\/news\/lambdavision-secures-starlab-leo-space-booking-with-voyager-technologies\/","title":{"rendered":"LambdaVision Secures Starlab LEO Space Booking with Voyager Technologies"},"content":{"rendered":"

\"LambdaVision<\/p>\n

LambdaVision<\/strong>, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, is advancing its commercialisation efforts by pre-booking commercial space in low-Earth orbit (LEO) through partnerships with Starlab Space LLC<\/strong>, a joint venture led by Voyager Technologies<\/strong>. This strategic agreement supports LambdaVision\u2019s plan to scale manufacturing of its protein-based artificial retina in space to benefit people with retinal degenerative diseases here on Earth and prepares the company for the scheduled 2030 retirement of the International Space Station (ISS).<\/p>\n

\u201cThis partnership with StarLab will allow us to continue to build on the significant momentum we have created toward our long- and short-term goals of leveraging LEO for both advancing our protein-based artificial retina toward commercialization and laying the groundwork for other potential commercial efforts in LEO,\u201d said Nicole Wagner<\/strong>, Ph.D., CEO of LambdaVision<\/strong>. \u201cOur hope is that our layer-by-layer technology, and this partnership for commercial space in LEO, will help build a thriving LEO economy even as the ISS readies for retirement.\u201d Through this agreement, LambdaVision has reserved payload slots and commercial space on Starlab’s next-generation commercial space station.<\/p>\n

\n

Also Read: Leveraging AI for Aerospace Systems Engineering: Enhancing Requirements Traceability in Space Missions<\/h4>\n<\/div>\n

\u201cLambdaVision has demonstrated the maturity of the science, engineering, and in-space manufacturing processes required to produce retinal implants in microgravity,\u201d said Luis Zea<\/strong>, Ph.D., chief scientist at Starlab<\/strong>. \u201cTheir reservation with Starlab enables the transition from demonstration to scalable, sustainable manufacturing, unlocking exponential growth while delivering meaningful benefits to patients on Earth. We are proud to work with LambdaVision to harness the unique advantages of microgravity to do good in the world.\u201d<\/p>\n

LambdaVision leverages microgravity to improve the layer-by-layer production process of their artificial retina through alternating layers of the protein bacteriorhodopsin and a polymer, supported by a membrane of a synthetic fiber that has long been used by the medical community. Reduced gravity in an LEO environment improves the homogeneity, stability, and performance of thin films like the protein-based artificial retina. By using proteins similar to the visual pigment rhodopsin naturally found in our eyes, LambdaVision\u2019s protein-based artificial retina mimics the light-absorbing properties of human photoreceptors, replacing the function of these damaged cells in the retinas of blind patients.<\/p>\n

\u201cLambdaVision is a perfect case study to show the transformative potential of Starlab\u2019s orbital platform for the biotech industry,\u201d said Ariel Ekblaw<\/strong>, CEO of Aurelia Institute and founder of MIT Space Exploration Initiative<\/strong>. \u201cPurpose-built infrastructure in space will empower a new generation of biotech companies \u2013 starting with LambdaVision \u2013 to pursue truly breakthrough advances. We are proud to support LambdaVision in their mission to leverage the space domain for the benefit of life on Earth and enthusiastically support their partnership with Starlab.\u201d<\/p>\n

\n

Also Read: What is Payload Integration in CubeSats & Small Satellites?<\/h4>\n<\/div>\n

While LambdaVision\u2019s first application is focused on restoring vision, its layer-by-layer protein manufacturing platform has broader potential that could enable highly uniform, stable protein films for sensitive biosensors, optical systems, tissue engineering, and drug delivery applications. Moreover, the pioneering hardware, systems, and processes associated with manufacturing a drug product in microgravity will demonstrate feasibility and inspire new research and commercial therapeutic development in LEO.<\/p>\n

\u201cLambdaVision\u2019s work represents an exciting step forward for life sciences in space. As investors in both LambdaVision and Voyager, we\u2019re excited to see LambdaVision\u2019s innovative artificial retina technology combined with Voyager\u2019s Starlab platform,\u201d said Rob Desborough<\/strong>, partner at Seraphim Space.<\/strong> \u201cTogether, they are demonstrating how orbital research can accelerate new therapies and expand the possibilities for commercial science in low-Earth orbit. It\u2019s inspiring to see companies working together to harness microgravity to benefit patients here on Earth.\u201d<\/p>\n

LambdaVision has recently closed a $7M seed funding round co-led by Seven Seven Six and Aurelia Foundry Fund, with additional support from Seraphim Space, providing runway into 2027. With this funding, the company continues to validate its innovative space-based manufacturing to benefit those on Earth. To date, LambdaVision has secured $22.0 million in funding and launched 9 missions to the ISS.<\/p>\n","protected":false},"excerpt":{"rendered":"

LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, is advancing its commercialisation efforts by pre-booking commercial space in low-Earth orbit (LEO) through partnerships with Starlab Space LLC, a joint venture led by Voyager Technologies. This strategic agreement supports LambdaVision\u2019s plan to scale manufacturing […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[39,38,20,45],"class_list":["post-1922","post","type-post","status-publish","format-standard","hentry","category-news","tag-aerospace","tag-leo","tag-satellite","tag-sensors"],"acf":[],"_links":{"self":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/1922"}],"collection":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/comments?post=1922"}],"version-history":[{"count":0,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/posts\/1922\/revisions"}],"wp:attachment":[{"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/media?parent=1922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/categories?post=1922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/starpath.global\/blog\/wp-json\/wp\/v2\/tags?post=1922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}